Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study Day  or who has not recovered (ie, ? Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) =<  days prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
COHORT : Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
COHORT : Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to cycle  day  or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to registration or who has not recovered (i.e., =< grade  or baseline) from adverse events due to agents administered >  weeks prior
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study Day  or not recovered from an adverse event caused by mAbs administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patient has received a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or baseline) from adverse events due to a previously administered agents
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to enrollment or who has not recovered from AEs due to mAb agents administered more than  weeks earlier.
Has received treatment with an anticancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study registration or who has not recovered (i.e. =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day , or targeted small molecule therapy within  weeks prior to study day , or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Participants must not have had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or have not recovered (i.e. =< grade  at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior, anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to Cycle /Day  or who has not recovered (i.e., ? Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier\r\n* Note: The use of denosumab is an exception to this criterion
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti?cancer monoclonal antibody (mAb) within  days prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  days earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Prior anti-cancer monoclonal antibody (mAb) =<  weeks prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks prior to registration
Has had a prior anti-cancer monoclonal antibody (mAb) within  days prior to on-study date or who has not recovered (i.e., ? grade  or baseline) from adverse events due to agents administered more than  weeks earlier; (subjects with ? grade  neuropathy are an exception to this criterion and may qualify for the study)
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) treatment within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., ? grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or baseline) from adverse events (AEs) due to agents administered more than  days earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or to baseline) from adverse events due to agents administered more than  weeks earlier; note that denosumab for treatment for bone metastases is allowed
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Received an anti-cancer monoclonal antibody (mAb) within  weeks prior to the first dose of study treatment or who has not recovered (i.e. ?Grade  or baseline) from AEs due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; if a patient has progressive or stable disease to prior regimen, rituximab is allowed up to  weeks prior to the initiation of study therapy
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Participants who have had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patient has received a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or baseline) from adverse events due to a previously administered agents
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to a previously administered agent
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) =<  weeks prior to registration or who has not recovered (i.e., =< grade  or at baseline level) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to such agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  (first day of SBRT treatment) or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (ie, =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; toxicities that are disease related will not exclude patients
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to first dose of MK- or has not recovered (i.e., to =< grade  or baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patient has not recovered to grade - from adverse events due to prior chemotherapy, radiation, or biological cancer therapy (including monoclonal antibody [mAb])
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study Day  or who has not recovered (i.e., ? Grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier.
Has had a prior monoclonal antibody (mAb) within  weeks prior to Study Day  or who has not recovered (i.e. ? Grade  or at baseline) from acute adverse events from prior mAb therapy NOTE: Subjects with ? Grade  neuropathy or Grade  alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed;
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day , or targeted small molecule therapy within  weeks prior to study day , or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier, with the exception of lymphopenia or asymptomatic aberrancies of sodium, amylase, lipase or alkaline phosphatase
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anticancer monoclonal antibody (mAb) within  weeks prior to study Day  or has not recovered (i.e. ? Grade  or at Baseline) from adverse events (AEs) due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  at baseline) from adverse events due to agents administered more than  weeks earlier
REGISTRATION TO TREATMENT (STEP ): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study registration or have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
REGISTRATION TO TREATMENT (STEP ): Patient must not have received a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study registration or have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to registration for protocol therapy or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  (excluding commercial or investigational anti-PD or anti-PD-L antibodies as single agents) or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier; patients who have autoimmune adverse events controlled by replacement therapy (i.e. hypothyroidism) due to previous treatment are eligible provided replacement therapy has been initiated and toxicity has returned to grade 
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer therapy with a monoclonal antibody (mAb) =<  weeks prior to registration OR failure to recover (to =< grade ) from adverse events (AE) attributable to agents received >  weeks prior to registration
Participants who have had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to cycle  day  or who have not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anticancer monoclonal antibody (mAb) within  weeks prior to first dose study therapy or who has not recovered (i.e., Grade ? or at baseline) from AEs due to mAbs administered > weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within  weeks prior to the first dose of study drug ( weeks for nitrosoureas or mitomycin C) or who has not recovered (i.e., ? Grade  or at Baseline) from adverse events (AEs) due to mAbs administered more than  weeks earlier.
Prior anti-cancer monoclonal antibody (mAb) therapy within  weeks prior to Study Day , or not recovered from adverse events
Prior anti-cancer therapy with a monoclonal antibody (mAb) within  weeks prior to study day  or not recovered from adverse events (improved to grade  or less) due to mAbs administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or has not recovered (i.e., =< grade  or at baseline) for adverse events (AEs) due to agents administered >  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., >= grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study Day  or not recovered from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within  weeks prior to study Day  or who has not recovered from adverse events due to agents administered more than  weeks earlier
Anti-cancer monoclonal antibody (mAb) within  weeks prior to study Day  or not recovered from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer monoclonal antibody (mAb) therapy within  weeks prior to study Day , or not recovered from adverse events due to agents administered more than  weeks earlier
Prior anti-cancer therapy with a monoclonal antibody (mAb) within  weeks prior to study Day  or not recovered from adverse events due to mAbs administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events (AE) due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior mAb within  weeks prior to study Day  or who has not recovered from adverse events due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy, radiotherapy, monoclonal antibody (mAb), or targeted small molecule therapy within  weeks of study registration are not eligible; those who have not recovered from adverse events (grade  or baseline) due to such agents administered more than  weeks earlier are not eligible
Prior anti-cancer monoclonal antibody (mAb) =<  weeks prior to registration or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered >=  weeks prior to registration
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior monoclonal antibody (mAb) within  weeks prior to first dose of study drug in the study or who has not recovered (i.e., ? Grade  or at baseline) from adverse events (AEs) due to agents administered more than  weeks earlier.
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
Has had a prior anti-cancer monoclonal antibody (mAb) within  weeks prior to study day  or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to agents administered more than  weeks earlier
